title: Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine.
abstract: Chromosomal translocations represent an important prognostic indicator in B-cell chronic lymphocytic leukemia (B-CLL). However, their value had been neither determined in homogeneously treated patients nor compared to that of IgV(H) mutational status. Sixty-five B-CLL patients were investigated using cytogenetics, interphase fluorescence in situ hybridization (FISH), analysis of IgV(H) and of TP53 mutational status before treatment with 2-chloro-2'-deoxyadenosine (CdA). Translocations (n=45) were detected in 42% of the patients, including both balanced (n=12) and unbalanced (n=33) types. IgV(H) was mutated in 43% of the patients. Patients with translocations were more heavily pretreated (P=0.05), presented with more complex karyotypes (P<0.001), 17p abnormalities and TP53 mutations, and had a higher failure rate (59 vs 21% in patients without translocations, P=0.004). Patients with unbalanced translocations displayed a shorter median treatment-free survival (TFS, 6.9 vs 35.9 months, log rank 22.72, P<0.001) and overall survival (OS, 13.0 vs 68.0 months, log rank 16.51, P<0.001), as compared to patients without translocation. In multivariate analysis, unbalanced translocations were independently associated with therapeutic failure, short TFS and short OS. IgV(H) mutational status was independently associated with risk of failure and TFS, but not OS. In B-CLL patients treated with CdA, translocations are strong predictors of outcome.
authors.affiliation: Department of Hematology/Hematological Biology, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium. vandenneste@sang.ucl.ac.be
authors.forename: E
authors.initials: E
authors.lastname: Van Den Neste
authors.forename: V
authors.initials: V
authors.lastname: Robin
authors.forename: J
authors.initials: J
authors.lastname: Francart
authors.forename: A
authors.initials: A
authors.lastname: Hagemeijer
authors.forename: M
authors.initials: M
authors.lastname: Stul
authors.forename: P
authors.initials: P
authors.lastname: Vandenberghe
authors.forename: A
authors.initials: A
authors.lastname: Delannoy
authors.forename: A
authors.initials: A
authors.lastname: Sonet
authors.forename: V
authors.initials: V
authors.lastname: Deneys
authors.forename: S
authors.initials: S
authors.lastname: Costantini
authors.forename: A
authors.initials: A
authors.lastname: Ferrant
authors.forename: A
authors.initials: A
authors.lastname: Robert
authors.forename: L
authors.initials: L
authors.lastname: Michaux
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002882:Chromosomes, Human, Pair 13 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D017338:Cladribine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007399:Interphase; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate; D014178:Translocation, Genetic; D017211:Treatment Failure; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D017338:Cladribine